NervGen Reports Third Quarter 2026 Financial Results and Provides Business Updates
Company plans to request a multidisciplinary Type B meeting with FDA to discuss NVG-291’s continued
Company plans to request a multidisciplinary Type B meeting with FDA to discuss NVG-291’s continued